Nashville, Tennessee 37208

  • Inflammatory Bowel Disease


The investigators are doing the research to discover genes that cause Inflammatory Bowel Disease (IBD) specifically in the African American population. African Americans with or without Crohn's disease or ulcerative colitis are eligible to join. If you agree to join the study, the investigators will ask for information about your health. The investigators will also ask you to give us a blood sample so that they may discover the genes that cause IBD. The blood sample may be collected at Johns Hopkins or any local facility convenient to you.

Study summary:

This current protocol was established as part of an NIDDK initiative to further explore genetic factors associated with IBD. Specifically, the investigators are interested in identifying the genetic, environment and socio-economical components that contribute to the development of IBD in the African American population. IBD is believed to be caused by a combination of environmental and genetic factors. Genetic data will be examined alongside potential environmental factors such as smoking, medications, environmental exposures, and some dietary factors. Since IBD is known to predominantly affect Western, industrialized areas of the world, the investigators will also inquire about participants' socioeconomic background in hopes of identifying any previously unknown factors in the AA population that may increase the risk of IBD. These potential environmental factors will be important in association analyses using covariates as these factors can obscure potential associations or interact with genetic factors and thus contribute to genetic associations. The investigators will also obtain information as to ancestry of parents and grandparents as to best match cases with unrelated controls of similar ancestry (e.g., Caribbean, recent European or recent African ancestry could cause genetic mismatch of a case and control). At the same time, the investigators will also collect similar information (smoking, medications, environmental exposures and dietary factors) from non-African Americans for the purpose of making direct comparisons for these parameters between the different racial groups to assess the contribution of non-genetic factors for susceptibility to the development of IBD. This study calls for recruiting AA patients and ethnically matched controls (friend or spouse). These persons will provide us with a blood sample and with information requested on a questionnaire asking the following: clinical course and history of their IBD or their general health, smoking history, socioeconomic variables and specific dietary factors known in some populations to be related to IBD etiology. Access to medical records will be used to confirm diagnoses. The clinical characteristics of IBD obtained from medical records will be summarized in a phenotyping form using a standardized NIDDK IBDGC Phenotyping Operations Manual. Controls will be asked health history to identify potentially unrecognized IBD. DNA and other biospecimens will be purified from blood. Samples and data will also be shared with the NIDDK IBDGC for use in IBDGC research projects and will be processed and maintained at NIDDK repositories.


Inclusion Criteria: 1. African Americans with a confirmed diagnosis of Inflammatory Bowel Disease (IBD) 2. African Americans without a diagnosis of IBD and without a family history of IBD for comparison purposes Exclusion Criteria: Patients whose IBD cannot be confirmed

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:


Brief Title:

Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)

Official Title:

Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)

Overall Status:


Study Phase:




Minimum Age:

5 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Johns Hopkins University

Oversight Authority:

United States: Institutional Review Board

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Mark Lazarev, MD
Principal Investigator
Johns Hopkins University
Primary Contact:Lisa Datta, MS

Study Dates

Start Date:June 2003
Completion Date:August 2027
Completion Type:Anticipated
Primary Completion Date:August 2027
Primary Completion Type:Anticipated
Verification Date:October 2022
Last Changed Date:October 31, 2022
First Received Date:June 16, 2010

Study Outcomes

There are no available Study Outcomes

Study Interventions

There are no available Study Interventions

Study Arms

Study Arm Type:Other
Arm Name:Affected
Description:Patients with IBD
Study Arm Type:Other
Arm Name:Unaffected
Description:Individuals who do not have IBD

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Johns Hopkins University
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Institutes of Health (NIH)

Samples and Retentions

Sample Retention:Samples With DNA
Description: whole blood and derivatives from blood, saliva
Study Population: Individuals diagnosed with Inflammatory Bowel Disease
Sample Method:Non-Probability Sample

Study References

There are no available Study References

Data Source:

Date Processed: March 21, 2023

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

If you would like to be contacted by the clinical trial representative please fill out the form below.